Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more
Myungmoon Phar (017180) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.006x
Based on the latest financial reports, Myungmoon Phar (017180) has a cash flow conversion efficiency ratio of -0.006x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-664.77 Million) by net assets (₩103.67 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Myungmoon Phar - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Myungmoon Phar's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Myungmoon Phar Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Myungmoon Phar ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shree Pushkar Chemicals & Fertilisers Limited
NSE:SHREEPUSHK
|
0.065x |
|
TRADEDOUBLER AB SK -40
F:T1D
|
N/A |
|
Atlas Engineered Products Ltd
PINK:APEUF
|
0.050x |
|
TradeDoubler AB
ST:TRAD
|
0.041x |
|
Moller Y Perez
SN:MOLLER
|
-0.019x |
|
M-POWER INFORMATION Co., LTD.
TWO:6874
|
0.148x |
|
Sunfon Construction Co Ltd
TWO:5514
|
-0.056x |
|
Dong-A Hwa Sung Co.Ltd
KQ:041930
|
0.049x |
Annual Cash Flow Conversion Efficiency for Myungmoon Phar (2010–2024)
The table below shows the annual cash flow conversion efficiency of Myungmoon Phar from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩103.12 Billion | ₩-1.34 Billion | -0.013x | +77.78% |
| 2023-12-31 | ₩88.75 Billion | ₩-5.18 Billion | -0.058x | -201.57% |
| 2022-12-31 | ₩95.27 Billion | ₩5.47 Billion | 0.057x | +477.20% |
| 2021-12-31 | ₩85.87 Billion | ₩855.00 Million | 0.010x | +105.42% |
| 2020-12-31 | ₩90.77 Billion | ₩-16.67 Billion | -0.184x | -400.89% |
| 2019-12-31 | ₩80.20 Billion | ₩-2.94 Billion | -0.037x | -129.92% |
| 2018-12-31 | ₩93.06 Billion | ₩11.41 Billion | 0.123x | +55.39% |
| 2017-12-31 | ₩101.72 Billion | ₩8.02 Billion | 0.079x | +33.34% |
| 2016-12-31 | ₩94.68 Billion | ₩5.60 Billion | 0.059x | +172.13% |
| 2015-12-31 | ₩67.12 Billion | ₩-5.50 Billion | -0.082x | -16457.33% |
| 2014-12-31 | ₩73.15 Billion | ₩-36.23 Million | 0.000x | -101.81% |
| 2013-12-31 | ₩73.20 Billion | ₩2.00 Billion | 0.027x | -28.27% |
| 2012-12-31 | ₩72.87 Billion | ₩2.78 Billion | 0.038x | -10.77% |
| 2010-12-31 | ₩67.13 Billion | ₩2.87 Billion | 0.043x | -- |